Five-year treatment outcomes in the ahmed baerveldt comparison study

Donald L. Budenz, Keith Barton, Steven J Gedde, William J Feuer, Joyce Schiffman, Vital P. Costa, David G. Godfrey, Yvonne M. Buys

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Purpose To compare the 5-year outcomes of the Ahmed FP7 Glaucoma Valve (AGV) (New World Medical, Cucamonga, CA) and the Baerveldt 101-350 Glaucoma Implant (BGI) (Abbott Medical Optics, Abbott Park, IL) for the treatment of refractory glaucoma. Design Multicenter, randomized, controlled clinical trial. Participants A total of 276 patients, including 143 in the AGV group and 133 in the BGI group. Methods Patients aged 18 to 85 years with previous intraocular surgery or refractory glaucoma and intraocular pressure (IOP) of ≥18 mmHg in whom glaucoma drainage implant (GDI) surgery was planned were randomized to implantation of an AGV or a BGI. Main Outcome Measures Surgical failure, IOP, visual acuity (VA), use of glaucoma medications, and complications. Results At 5 years, IOP (mean ± standard deviation [SD]) was 14.7±4.4 mmHg in the AGV group and 12.7±4.5 mmHg in the BGI group (P = 0.015). The number of glaucoma medications in use at 5 years (mean ± SD) was 2.2±1.4 in the AGV group and 1.8±1.5 in the BGI group (P = 0.28). The cumulative probability of failure during 5 years of follow-up was 44.7% in the AGV group and 39.4% in the BGI group (P = 0.65). The number of subjects failing because of inadequately controlled IOP or reoperation for glaucoma was 46 in the AGV group (80% of AGV failures) and 25 in the BGI group (53% of BGI failures; P = 0.003). Eleven eyes in the AGV group (20% of AGV failures) experienced persistent hypotony, explantation of implant, or loss of light perception compared with 22 eyes (47% of failures) in the BGI group. Change in logarithm of the minimum angle of resolution VA (mean ± SD) at 5 years was 0.42±0.99 in the AGV group and 0.43±0.84 in the BGI group (P = 0.97). Conclusions Similar rates of surgical success were observed with both implants at 5 years. The BGI produced greater IOP reduction and a lower rate of glaucoma reoperation than the AGV, but the BGI was associated with twice as many failures because of safety issues.

Original languageEnglish
Pages (from-to)308-316
Number of pages9
JournalOphthalmology
Volume122
Issue number2
DOIs
StatePublished - Jan 1 2015

Fingerprint

Glaucoma
Intraocular Pressure
Reoperation
Visual Acuity
Glaucoma Drainage Implants

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Budenz, D. L., Barton, K., Gedde, S. J., Feuer, W. J., Schiffman, J., Costa, V. P., ... Buys, Y. M. (2015). Five-year treatment outcomes in the ahmed baerveldt comparison study. Ophthalmology, 122(2), 308-316. https://doi.org/10.1016/j.ophtha.2014.08.043

Five-year treatment outcomes in the ahmed baerveldt comparison study. / Budenz, Donald L.; Barton, Keith; Gedde, Steven J; Feuer, William J; Schiffman, Joyce; Costa, Vital P.; Godfrey, David G.; Buys, Yvonne M.

In: Ophthalmology, Vol. 122, No. 2, 01.01.2015, p. 308-316.

Research output: Contribution to journalArticle

Budenz, DL, Barton, K, Gedde, SJ, Feuer, WJ, Schiffman, J, Costa, VP, Godfrey, DG & Buys, YM 2015, 'Five-year treatment outcomes in the ahmed baerveldt comparison study', Ophthalmology, vol. 122, no. 2, pp. 308-316. https://doi.org/10.1016/j.ophtha.2014.08.043
Budenz DL, Barton K, Gedde SJ, Feuer WJ, Schiffman J, Costa VP et al. Five-year treatment outcomes in the ahmed baerveldt comparison study. Ophthalmology. 2015 Jan 1;122(2):308-316. https://doi.org/10.1016/j.ophtha.2014.08.043
Budenz, Donald L. ; Barton, Keith ; Gedde, Steven J ; Feuer, William J ; Schiffman, Joyce ; Costa, Vital P. ; Godfrey, David G. ; Buys, Yvonne M. / Five-year treatment outcomes in the ahmed baerveldt comparison study. In: Ophthalmology. 2015 ; Vol. 122, No. 2. pp. 308-316.
@article{fcff5ea7bffb404f8d818a6fb7ff0707,
title = "Five-year treatment outcomes in the ahmed baerveldt comparison study",
abstract = "Purpose To compare the 5-year outcomes of the Ahmed FP7 Glaucoma Valve (AGV) (New World Medical, Cucamonga, CA) and the Baerveldt 101-350 Glaucoma Implant (BGI) (Abbott Medical Optics, Abbott Park, IL) for the treatment of refractory glaucoma. Design Multicenter, randomized, controlled clinical trial. Participants A total of 276 patients, including 143 in the AGV group and 133 in the BGI group. Methods Patients aged 18 to 85 years with previous intraocular surgery or refractory glaucoma and intraocular pressure (IOP) of ≥18 mmHg in whom glaucoma drainage implant (GDI) surgery was planned were randomized to implantation of an AGV or a BGI. Main Outcome Measures Surgical failure, IOP, visual acuity (VA), use of glaucoma medications, and complications. Results At 5 years, IOP (mean ± standard deviation [SD]) was 14.7±4.4 mmHg in the AGV group and 12.7±4.5 mmHg in the BGI group (P = 0.015). The number of glaucoma medications in use at 5 years (mean ± SD) was 2.2±1.4 in the AGV group and 1.8±1.5 in the BGI group (P = 0.28). The cumulative probability of failure during 5 years of follow-up was 44.7{\%} in the AGV group and 39.4{\%} in the BGI group (P = 0.65). The number of subjects failing because of inadequately controlled IOP or reoperation for glaucoma was 46 in the AGV group (80{\%} of AGV failures) and 25 in the BGI group (53{\%} of BGI failures; P = 0.003). Eleven eyes in the AGV group (20{\%} of AGV failures) experienced persistent hypotony, explantation of implant, or loss of light perception compared with 22 eyes (47{\%} of failures) in the BGI group. Change in logarithm of the minimum angle of resolution VA (mean ± SD) at 5 years was 0.42±0.99 in the AGV group and 0.43±0.84 in the BGI group (P = 0.97). Conclusions Similar rates of surgical success were observed with both implants at 5 years. The BGI produced greater IOP reduction and a lower rate of glaucoma reoperation than the AGV, but the BGI was associated with twice as many failures because of safety issues.",
author = "Budenz, {Donald L.} and Keith Barton and Gedde, {Steven J} and Feuer, {William J} and Joyce Schiffman and Costa, {Vital P.} and Godfrey, {David G.} and Buys, {Yvonne M.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.ophtha.2014.08.043",
language = "English",
volume = "122",
pages = "308--316",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Five-year treatment outcomes in the ahmed baerveldt comparison study

AU - Budenz, Donald L.

AU - Barton, Keith

AU - Gedde, Steven J

AU - Feuer, William J

AU - Schiffman, Joyce

AU - Costa, Vital P.

AU - Godfrey, David G.

AU - Buys, Yvonne M.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose To compare the 5-year outcomes of the Ahmed FP7 Glaucoma Valve (AGV) (New World Medical, Cucamonga, CA) and the Baerveldt 101-350 Glaucoma Implant (BGI) (Abbott Medical Optics, Abbott Park, IL) for the treatment of refractory glaucoma. Design Multicenter, randomized, controlled clinical trial. Participants A total of 276 patients, including 143 in the AGV group and 133 in the BGI group. Methods Patients aged 18 to 85 years with previous intraocular surgery or refractory glaucoma and intraocular pressure (IOP) of ≥18 mmHg in whom glaucoma drainage implant (GDI) surgery was planned were randomized to implantation of an AGV or a BGI. Main Outcome Measures Surgical failure, IOP, visual acuity (VA), use of glaucoma medications, and complications. Results At 5 years, IOP (mean ± standard deviation [SD]) was 14.7±4.4 mmHg in the AGV group and 12.7±4.5 mmHg in the BGI group (P = 0.015). The number of glaucoma medications in use at 5 years (mean ± SD) was 2.2±1.4 in the AGV group and 1.8±1.5 in the BGI group (P = 0.28). The cumulative probability of failure during 5 years of follow-up was 44.7% in the AGV group and 39.4% in the BGI group (P = 0.65). The number of subjects failing because of inadequately controlled IOP or reoperation for glaucoma was 46 in the AGV group (80% of AGV failures) and 25 in the BGI group (53% of BGI failures; P = 0.003). Eleven eyes in the AGV group (20% of AGV failures) experienced persistent hypotony, explantation of implant, or loss of light perception compared with 22 eyes (47% of failures) in the BGI group. Change in logarithm of the minimum angle of resolution VA (mean ± SD) at 5 years was 0.42±0.99 in the AGV group and 0.43±0.84 in the BGI group (P = 0.97). Conclusions Similar rates of surgical success were observed with both implants at 5 years. The BGI produced greater IOP reduction and a lower rate of glaucoma reoperation than the AGV, but the BGI was associated with twice as many failures because of safety issues.

AB - Purpose To compare the 5-year outcomes of the Ahmed FP7 Glaucoma Valve (AGV) (New World Medical, Cucamonga, CA) and the Baerveldt 101-350 Glaucoma Implant (BGI) (Abbott Medical Optics, Abbott Park, IL) for the treatment of refractory glaucoma. Design Multicenter, randomized, controlled clinical trial. Participants A total of 276 patients, including 143 in the AGV group and 133 in the BGI group. Methods Patients aged 18 to 85 years with previous intraocular surgery or refractory glaucoma and intraocular pressure (IOP) of ≥18 mmHg in whom glaucoma drainage implant (GDI) surgery was planned were randomized to implantation of an AGV or a BGI. Main Outcome Measures Surgical failure, IOP, visual acuity (VA), use of glaucoma medications, and complications. Results At 5 years, IOP (mean ± standard deviation [SD]) was 14.7±4.4 mmHg in the AGV group and 12.7±4.5 mmHg in the BGI group (P = 0.015). The number of glaucoma medications in use at 5 years (mean ± SD) was 2.2±1.4 in the AGV group and 1.8±1.5 in the BGI group (P = 0.28). The cumulative probability of failure during 5 years of follow-up was 44.7% in the AGV group and 39.4% in the BGI group (P = 0.65). The number of subjects failing because of inadequately controlled IOP or reoperation for glaucoma was 46 in the AGV group (80% of AGV failures) and 25 in the BGI group (53% of BGI failures; P = 0.003). Eleven eyes in the AGV group (20% of AGV failures) experienced persistent hypotony, explantation of implant, or loss of light perception compared with 22 eyes (47% of failures) in the BGI group. Change in logarithm of the minimum angle of resolution VA (mean ± SD) at 5 years was 0.42±0.99 in the AGV group and 0.43±0.84 in the BGI group (P = 0.97). Conclusions Similar rates of surgical success were observed with both implants at 5 years. The BGI produced greater IOP reduction and a lower rate of glaucoma reoperation than the AGV, but the BGI was associated with twice as many failures because of safety issues.

UR - http://www.scopus.com/inward/record.url?scp=84921460861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921460861&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2014.08.043

DO - 10.1016/j.ophtha.2014.08.043

M3 - Article

C2 - 25439606

AN - SCOPUS:84921460861

VL - 122

SP - 308

EP - 316

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 2

ER -